María Paula Palacios‐Ortiz

María Paula Palacios‐Ortiz

Auto-generated profile, based on publicly available information

María Paula Palacios‐Ortiz

Universidad San Francisco de Quito Quito Ecuador

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2025 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
Laura GhanemLaura Ghanem
Laura Ghanem
NKNajwaa Kirmani
Najwaa Kirmani
NFNathalia De León Fernández
Nathalia De León Fernández
MPMaría Paula Palacios‐Ortiz
María Paula Palacios‐Ortiz
JRJuan David Rodríguez‐Parra
Juan David Rodríguez‐Parra
CRCorina A. Rusu
Corina A. Rusu
Background: Adult acne vulgaris is a chronic inflammatory skin condition that primarily affects females. Initial management includes topical and oral medications, but important limitations include ineffectiveness, nonadherence, and adverse effects. Spironolactone has shown good results in off‐label acne management.Aims: We aim to conduct a systematic review and meta‐analysis exploring the safety and efficacy of oral spironolactone for females with acne.Methods: We searched PubMed, Embase, and Cochrane for randomized controlled trials (RCTs) comparing oral spironolactone in women with acne to placebo. The primary endpoint was the objective assessment of acne improvement. Secondary endpoints included subjective assessment and adverse events. Statistical analysis was performed using Review Manager 5.4. Heterogeneity was assessed with I2 statistics.Results: We included 563 patients from 5 RCTs, of which 251 (42.9%) received spironolactone. Objective assessment of acne improvement (OR 6.59; 95% 3.50–12.43; p < 0.00001; I2 = 0%) was sixfold higher in the spironolactone group compared with placebo. Subjective assessment showed no difference between the two groups (OR 5.22; 95% 0.62–44.24; p < 0.13; I2 = 85%). Menstrual irregularities (OR 1.09; 95% 0.37–3.25; p = 0.88; I2 = 33%) and breast enlargement (OR 1.37; 95% 0.79–2.38; p = 0.26; I2 = 0%) were nonsignificant in patients taking spironolactone. Trial sequential analysis (TSA) confirmed that the required sample size was reached, favoring spironolactone over placebo.Conclusion: Our study suggests that oral spironolactone improves acne in female patients compared to placebo without increasing risks; thus, it should be elevated from “off‐label” use to an officially recommended standard of care.PROSPERO Registration: CRD42024626984.